Exploring the Next Frontier in Protein Degradation: Neurological Diseases

Targeted protein degradation is expanding beyond oncology and gaining traction in neurological diseases. With two approved assets for movement disorders and emerging first-in-human data from ARV-102 (Arvinas) showing oral bioavailability, blood–brain barrier penetration, and central target reduction, the field is entering a pivotal phase.

As degraders demonstrate potential against toxic protein aggregation, a hallmark of many neurodegenerative disorders, they’re reshaping therapeutic possibilities where traditional approaches have fallen short. Download the report to explore the data driving this next frontier in targeted protein degradation.